MiR-29c-3p Targets KDM5B to Suppress ESCC Progression and Enhance Anti-PD-L1-Related Immune Activation In Vitro
: Background: Immune checkpoint blockade against programmed death-ligand 1 (PD-L1) benefits only a subset of patients with esophageal squamous cell carcinoma (ESCC). The histone demethylase lysine-specific demethylase 5B (KDM5B) drives tumor growth, yet whether it also modulates anti-tumor immunity in ESCC is unknown....